Clinical Trials Logo

Male Breast Cancer clinical trials

View clinical trials related to Male Breast Cancer.

Filter by:

NCT ID: NCT00132002 Terminated - Clinical trials for Stage IV Breast Cancer

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00095888 Terminated - Clinical trials for Stage IV Breast Cancer

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells

NCT ID: NCT00071942 Terminated - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Start date: October 2003
Phase: Phase 1
Study type: Interventional

Vaccines may make the body build an immune response to kill tumor cells. This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic breast cancer.

NCT ID: NCT00063934 Terminated - Clinical trials for Stage IV Breast Cancer

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of oblimersen when given together with doxorubicin and docetaxel and to see how well they work in treating women with metastatic or locally advanced breast cancer. Drugs used in chemotherapy, such as doxorubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin and docetaxel by making the tumor cells more sensitive to the drugs.

NCT ID: NCT00039455 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer